Biopharmaceutical Company Announces FDA Approval For MDS Treatment
Geron Announces FDA Approval of RYTELO™ (Imetelstat) for Lower-Risk MDS with Transfusion-Dependent Anemia.
On June 7, 2024, Geron Corporation, a commercial-stage biopharmaceutical company, proudly announced that the U.S. Food and Drug Administration (FDA) has approved RYTELO™ (imetelstat), marking a milestone in the treatment of adult patients with lower-risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia. This approval encompasses patients who have not responded to or are ineligible for erythropoiesis-stimulating agents (ESA), offering new hope for those living with this debilitating condition. $Geron(GERN.US$
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
